Monoclonal antibodies and checkpoint inhibitors for multiple myeloma
New targets to treat acute myeloid leukemia (AML) with FLT3 mutations
Clinical trials, pathologies and developments in personalized medicine
Francesco d'Amore et al.
The future is bright for hematological oncology: promising areas for 2018 and beyond
The progress of CLL research: towards targeted therapy